Premium
N‐0923, a selective dopamine D 2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease
Author(s) -
Belluzzi J. D.,
Domino E. F.,
May J. M.,
Bankiewicz K. S.,
McAfee D. A.
Publication year - 1994
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870090204
Subject(s) - dopamine , agonist , endocrinology , medicine , sch 23390 , dopamine agonist , substantia nigra , bromocriptine , chemistry , dopamine receptor , mptp , receptor , prolactin , dopaminergic , hormone
Certain aminotetralins are known to be potent dopamine D 2 receptor agonists. N‐0923, [‐]2‐(N‐propyl‐N‐2‐thienylethylamino)‐5‐hydroxytetralin HCl, recognizes the high and low affinity states of the D 2 receptor in membranes from bovine caudate with a K low of 79 nM. The selectivity ratio is D 2 /D 1 = 15 and D 2 /α 2 = 1.4. N‐0923 also inhibits dopamine uptake and prolactin secretion, and it is an antagonist at the α 2 receptor. N‐0923 (3–300 nmol/kg, s.c.) induced dose‐dependent contralateral turning behavior in rats with unilateral 6‐hydroxydopamine lesions of the substantia nigra. The ED 50 of 30 nmol/kg was effective for 1 h. The positive enantiomer (N‐0924; 300 nmol/kg, s. c.) was without effect. A hemiparkinsonian syndrome was induced in four Macaca nemestrina monkeys by unilateral infusion of the neurotoxin MPTP into the right carotid artery. Video recordings of free‐moving behavior revealed bradykinesia, disuse of the contralateral upper limb and turning in a direction ipsilateral to the lesion. N‐0923 (3–300 nmol/kg, i.m.) induced contralateral turning behavior, exploratory activity, and contralateral limb usage. The ED 50 for turning (30 nmol/kg) was effective for 0.5 h. The potency order for induction of contralateral rotations was (+)‐PHNON‐0923 > bromocriptine. N‐0924 (300 nmol/kg, i. m.) was ineffective. We conclude that N‐0923 may be useful as a therapeutic agent in the treatment of Parkinson's disease.